Page last updated: 2024-11-12

alfibrate

Description

alfibrate: Al salt of clofibric acid; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Synonym
alufibrate
atherolip
aluminum, bis(2-(4-chlorophenoxy-kappao)-2-methylpropanoateo-kappao)hydroxy-
einecs 246-477-0
alfibrate
aluminum, bis(2-(p-chlorophenoxy)-2-methylpropionato)hydroxy-
clofibrato de aluminio [inn-spanish]
aluminii clofibras [inn-latin]
clofibrate d'aluminium [inn-french]
hydroxybis(2-(p-chlorophenoxy)isobutyric acid) aluminum
hydroxy bis-(2-(p-chlorophenoxy)isobutyric acid)-aluminum
aluminum, bis(2-(4-chlorophenoxy)-2-methylpropanoato-o1,o2)hydroxy-
D01208
aluminum clofibrate (jan/inn)
alfibrate (tn)
aluminum clofibrate [inn:ban:jan]
aluminum bis(alpha-para-chlorophenoxy)isobutyrate
aluminii clofibras
clofibrate d'aluminium
clofibrato de aluminio
unii-56203t2k2x
14613-01-5
SCHEMBL3344
alufibrat
bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate
CHEBI:31194
DTXSID70905093
aluminumclofibrate
alfibrate; alufibrate;aluminum clofibrate; atherolip; atherolip

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (83.33%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	1 (16.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	5.17	4	3	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofibric acid Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.	5.98	6	5	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
pirozadil pirozadil: structure	4.6	3	2	trihydroxybenzoic acid
plafibride plafibride: morpholino-methylurea analog of clofibric acid	3.34	1	1	aromatic ether
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	3.33	1	1	boron group element atom; elemental aluminium; metal atom

Condition	Relationship Strength	Studies	Trials
Coronary Heart Disease [description not available]	4.31	2	2
Elevated Cholesterol [description not available]	3.34	1	1
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	4.31	2	2
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	3.34	1	1
Hyperlipoproteinemia [description not available]	1.96	1	0
Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.	1.96	1	0
Complications of Diabetes Mellitus [description not available]	3.35	1	1
Hyperlipemia [description not available]	4.31	2	2
Hyperlipidemias Conditions with excess LIPIDS in the blood.	4.31	2	2